Bioatla Inc

BioAtla, Inc. is a clinical-stage biopharmaceutical company that develops specific and selective antibody-based therapeutics for solid tumor cancers. Its lead candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC), and ozuriftabmab vedotin (BA3021), a CAB ADC for melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate for adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3; and a preclinical candidate for CAB-Nectin 4 x CAB-CD3. Founded in 2007, BioAtla is headquartered in San Diego, California.